On May 5, 2026, Avalo Therapeutics, Inc. announced an underwriting agreement to sell 19,730,000 shares of common stock at $17.75 each, expecting to raise approximately $405 million for clinical development and general corporate purposes. The offering is set to close on May 7, 2026, and includes the issuance of pre-funded warrants for additional shares.